Supernus Pharmaceuticals is a pharmaceutical company that develops and commercialises medicines for central nervous system conditions. Its products treat epilepsy and attention deficit hyperactivity disorder, and it also markets treatments for migraine and movement disorders. The company serves patients and prescribers through neurologists, psychiatrists and other specialists, and it carries out its own research and development alongside its commercial operations. Supernus Pharmaceuticals is based in Rockville, Maryland, in the United States.
On this site Supernus Pharmaceuticals, Inc. appears as a stock on the London Stock Exchange (UK), code 0LB2, with prices in US dollars (USD). Dividend data for this stock is not available yet. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #3235 of 3788 on the London Stock Exchange · confidence Medium
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
24/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-15.0%
From 52-week high-28.0%
MomentumWeak
19/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-15.3%
6-month return-19.4%
Stability (higher is calmer)Weak
43/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)39.1%
Worst drawdown, 1 year (smaller is calmer)-32.2%
LiquidityWeak
10/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.01M USD
Zero-volume days11.7%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 37.96 – 59.74Daily closes, split-adjusted
Signals
50-day average43.30
200-day average47.62
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.25
Technical summary
Daily
Strongly bearish
1 bullish · 4 neutral · 10 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 6 bearish
Monthly
Strongly bearish
0 bullish · 0 neutral · 1 bearish
Moving averages (daily)
SMA 10
40.42
Bullish
EMA 10
40.74
Bearish
SMA 20
41.59
Bearish
EMA 20
41.38
Bearish
SMA 50
43.30
Bearish
EMA 50
42.95
Bearish
SMA 100
44.90
Bearish
EMA 100
44.58
Bearish
SMA 200
47.62
Bearish
EMA 200
–
n/a
Oscillators (daily)
RSI (14)
44.44
Neutral
MACD (12, 26)
-0.87
Bearish
Momentum (12)
-4.84
Bearish
Stochastic %K (14)
45.50
Neutral
Williams %R (14)
-54.50
Neutral
CCI (20)
-67.30
Neutral
Pivot points (classic, last session)
S3
40.48
S2
40.48
S1
40.48
Pivot
40.48
R1
40.48
R2
40.48
R3
40.48
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in USD. Educational only, not financial advice.
